The amylin field is heat­ing up ahead of No­vo Nordisk’s much-an­tic­i­pat­ed Ca­griSe­ma read­out lat­er this year.

The US Gov­ern­ment Ac­count­abil­i­ty Of­fice pub­lished a new re­port de­tail­ing con­cerns with the staffing of the FDA’s ...

Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...

Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...

TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...

John­son & John­son is su­ing the fed­er­al gov­ern­ment over its re­buke of the com­pa­ny’s al­ter­na­tive mod­el for 340B ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

Otsuka Pharmaceutical Factory and ICU Medical have formed a $200 million joint venture to bolster the US IV product supply ...

Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

A lot of Am­gen’s fu­ture rides on its ex­per­i­men­tal obe­si­ty med­i­cine Mar­i­Tide. At least in the minds of in­vestors.

Flag­ship Pi­o­neer­ing has ap­point­ed two new CEO-part­ners to ad­vise its port­fo­lio com­pa­nies and help steer its ...